Key result
Concomitant use of calcium channel blockers, renin-angiotensin system inhibitors, and cisplatin was associated with a higher risk of acute kidney injury (adjusted ROR 7.28; 95% CI 5.56-9.54).
Why the study?
There is limited evidence about the nephrotoxicity of calcium channel blockers and renin-angiotensin system inhibitors with concomitant cisplatin.
Does the concomitant use of calcium channel blockers and renin-angiotensin system inhibitors increase the risk of acute kidney injury in patients receiving cisplatin?
Observational (n=544,864)
Does the concomitant use of calcium channel blockers and renin-angiotensin system inhibitors increase the risk of acute kidney injury in patients receiving cisplatin?
Odds Ratio: 7.28 (95% CI 5.56–9.54)
Concomitant use of calcium channel blockers and renin-angiotensin system inhibitors significantly increases the reporting odds of acute kidney injury in patients receiving cisplatin.
May warrant closer renal monitoring with this combination; leaves open confirmation in prospective studies.
BACKGROUND/AIM: There is limited evidence about the nephrotoxicity of calcium channel blockers (CCBs) and renin-angiotensin system (RAS) inhibitors with concomitant cisplatin (CDDP). We investigated whether combinations of antihypertensive drugs are associated with CDDP-related acute kidney injury (AKI) using the Japanese Adverse Drug Event Report database. PATIENTS AND METHODS: We analysed 544,864 reports in the database from 2004 to 2020. A reporting odds ratio (ROR) and confidence interval (CI) with adjustment for potential confounding factors was calculated for AKI for each drug and the combined use of the drugs and CDDP. RESULTS: CDDP, CCBs, and RAS inhibitors were all detected signals for AKI. The ROR in cases with concomitant use of CCBs, RAS inhibitors, and CDDP (adjusted ROR 7.28; 95% CI=5.56-9.54) was higher than that in cases with use of each drug. CONCLUSION: AKI may require more attention when patients receiving CDDP take CCBs and RAS inhibitors together.
No takes yet. Share an insight, caveat, or question.
Takeuchi et al. (2022) conducted an observational in Cisplatin-induced Acute Kidney Injury (n=544,864). Concomitant use of calcium channel blockers (CCBs), renin-angiotensin system (RAS) inhibitors, and cisplatin (CDDP) vs. Use of each drug alone was evaluated on Acute kidney injury (AKI) (adjusted ROR 7.28, 95% CI 5.56-9.54). Concomitant use of calcium channel blockers, renin-angiotensin system inhibitors, and cisplatin was associated with a higher risk of acute kidney injury (adjusted ROR 7.28; 95% CI 5.56-9.54).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: